LOUISVILLE, Ky. -- Tumor outcomes and thrombus control in renal cell carcinoma (RCC) improved with perioperative treatment that included a targeted agent plus immunotherapy, a small retrospective ...
The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey. Oncologists appear to prefer an immunotherapy (IO)/IO combination compared with an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback